NASDAQ:URGN UroGen Pharma (URGN) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free URGN Stock Alerts $13.45 -0.40 (-2.89%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$13.16▼$14.2650-Day Range$12.95▼$18.4252-Week Range$8.69▼$24.13Volume424,250 shsAverage Volume327,698 shsMarket Capitalization$315.40 millionP/E RatioN/ADividend YieldN/APrice Target$46.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get UroGen Pharma alerts: Email Address UroGen Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside247.0% Upside$46.67 Price TargetShort InterestBearish17.91% of Shares Sold ShortDividend StrengthN/ASustainability-1.33Upright™ Environmental ScoreNews Sentiment0.20Based on 8 Articles This WeekInsider TradingSelling Shares$168,600 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.59) to ($1.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.95 out of 5 starsMedical Sector185th out of 903 stocksPharmaceutical Preparations Industry76th out of 420 stocks 3.5 Analyst's Opinion Consensus RatingUroGen Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageUroGen Pharma has only been the subject of 2 research reports in the past 90 days.Read more about UroGen Pharma's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.91% of the outstanding shares of UroGen Pharma have been sold short.Short Interest Ratio / Days to CoverUroGen Pharma has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in UroGen Pharma has recently increased by 0.24%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldUroGen Pharma does not currently pay a dividend.Dividend GrowthUroGen Pharma does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUroGen Pharma has received a 70.26% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Other cancer medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for UroGen Pharma is -1.33. Previous Next 2.3 News and Social Media Coverage News SentimentUroGen Pharma has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for UroGen Pharma this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for URGN on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows3 people have added UroGen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, UroGen Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $168,600.00 in company stock.Percentage Held by Insiders11.13% of the stock of UroGen Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.29% of the stock of UroGen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about UroGen Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for UroGen Pharma are expected to grow in the coming year, from ($3.59) to ($1.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of UroGen Pharma is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of UroGen Pharma is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about UroGen Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About UroGen Pharma Stock (NASDAQ:URGN)UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.Read More URGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart URGN Stock News HeadlinesMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Urogen Pharma on Strong Clinical Data and Market PotentialMay 5, 2024 | businesswire.comNew Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction TherapyMay 7, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. May 4, 2024 | businesswire.comUroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024May 4, 2024 | businesswire.comNew Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal TrialMay 3, 2024 | businesswire.comUroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024April 18, 2024 | markets.businessinsider.comBuy Rating Affirmed for Urogen Pharma Amid Promising Clinical Data and Strategic Conference PresentationsApril 17, 2024 | businesswire.comUroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial CancersMay 7, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 16, 2024 | investing.comUroGen's UGN-103 advances to Phase 3 for bladder cancerApril 15, 2024 | businesswire.comUroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerApril 14, 2024 | finance.yahoo.comUroGen Pharma Ltd.'s (NASDAQ:URGN) high institutional ownership speaks for itself as stock continues to impress, up 11% over last weekApril 4, 2024 | markets.businessinsider.comUrogen Pharma’s Strategic Defense and Pipeline Progress Bolster Buy RatingMarch 18, 2024 | seekingalpha.comUroGen: All Eyes On UGN-102March 17, 2024 | finance.yahoo.comUroGen Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineMarch 15, 2024 | finance.yahoo.comUroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Urogen Pharma (URGN) and Cullinan Management (CGEM)March 14, 2024 | finanznachrichten.deUroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102March 14, 2024 | finance.yahoo.comUroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial ChallengesMarch 14, 2024 | investorplace.comURGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023March 14, 2024 | finance.yahoo.comUroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102March 13, 2024 | markets.businessinsider.comUroGen Pharma earnings preview: what to expectMarch 8, 2024 | businesswire.comUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 4, 2024 | finance.yahoo.comUroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024March 1, 2024 | stocknews.com3 Biotech Stocks Climbing the Ranks to WatchMarch 1, 2024 | msn.comUroGen falls as Teva seeks FDA nod for Jelmyto genericFebruary 26, 2024 | businesswire.comUroGen Pharma to Present at TD Cowen 44th Annual Health Care ConferenceSee More Headlines Receive URGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today5/07/2024Next Earnings (Confirmed)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:URGN CUSIPN/A CIK1668243 Webwww.urogen.com Phone(646) 768-9780FaxN/AEmployees198Year FoundedN/APrice Target and Rating Average Stock Price Target$46.67 High Stock Price Target$54.00 Low Stock Price Target$34.00 Potential Upside/Downside+247.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,240,000.00 Net Margins-123.61% Pretax Margin-118.87% Return on EquityN/A Return on Assets-70.48% Debt Debt-to-Equity RatioN/A Current Ratio5.42 Quick Ratio5.24 Sales & Book Value Annual Sales$82.71 million Price / Sales3.81 Cash FlowN/A Price / Cash FlowN/A Book Value($2.78) per share Price / Book-4.84Miscellaneous Outstanding Shares23,450,000Free Float20,844,000Market Cap$315.40 million OptionableOptionable Beta1.09 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMs. Elizabeth A. Barrett (Age 62)President, CEO & Director Comp: $1.12MMr. Dong Kim (Age 47)Chief Financial Officer Comp: $546.68kMr. Jason Drew Smith (Age 52)General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $717.58kVincent I. PerroneSenior Director of Investor RelationsMr. Bryon WornsonExecutive Vice President of Talent, Advocacy & CommunicationsDr. Sari Prutchi-Sagiv Ph.D.Marketing DirectorDr. Marina KonortyExecutive Vice President of Research & Development and Technical OperationsDr. Mark P. Schoenberg M.D. (Age 66)Chief Medical Officer Comp: $579.5kMr. Jeffrey Bova M.B.A.Chief Commercial OfficerMr. James Ottinger R.ph.Executive Vice President of Regulatory Affairs & QualityMore ExecutivesKey CompetitorsTerns PharmaceuticalsNASDAQ:TERNRani TherapeuticsNASDAQ:RANIPrecigenNASDAQ:PGENNkartaNASDAQ:NKTXAtai Life SciencesNASDAQ:ATAIView All CompetitorsInsiders & InstitutionsOak Ridge Investments LLCBought 61,204 shares on 5/1/2024Ownership: 0.261%BNP Paribas Financial MarketsBought 16,799 shares on 5/1/2024Ownership: 0.170%Harel Insurance Investments & Financial Services Ltd.Sold 196,558 shares on 4/30/2024Ownership: 2.872%China Universal Asset Management Co. Ltd.Bought 2,328 shares on 4/29/2024Ownership: 0.025%Mark SchoenbergSold 12,000 sharesTotal: $168,600.00 ($14.05/share)View All Insider TransactionsView All Institutional Transactions URGN Stock Analysis - Frequently Asked Questions Should I buy or sell UroGen Pharma stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" URGN shares. View URGN analyst ratings or view top-rated stocks. What is UroGen Pharma's stock price target for 2024? 2 analysts have issued 12-month target prices for UroGen Pharma's shares. Their URGN share price targets range from $34.00 to $54.00. On average, they expect the company's stock price to reach $46.67 in the next year. This suggests a possible upside of 247.0% from the stock's current price. View analysts price targets for URGN or view top-rated stocks among Wall Street analysts. How have URGN shares performed in 2024? UroGen Pharma's stock was trading at $15.00 on January 1st, 2024. Since then, URGN stock has decreased by 10.3% and is now trading at $13.45. View the best growth stocks for 2024 here. When is UroGen Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our URGN earnings forecast. How can I listen to UroGen Pharma's earnings call? UroGen Pharma will be holding an earnings conference call on Monday, May 13th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were UroGen Pharma's earnings last quarter? UroGen Pharma Ltd. (NASDAQ:URGN) issued its quarterly earnings data on Thursday, March, 14th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.05. The company had revenue of $23.53 million for the quarter, compared to the consensus estimate of $22.30 million. What ETFs hold UroGen Pharma's stock? ETFs with the largest weight of UroGen Pharma (NASDAQ:URGN) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL).Amplify BlueStar Israel Technology ETF (ITEQ). What other stocks do shareholders of UroGen Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU). When did UroGen Pharma IPO? UroGen Pharma (URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers. Who are UroGen Pharma's major shareholders? UroGen Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Harel Insurance Investments & Financial Services Ltd. (2.87%), Oak Ridge Investments LLC (0.26%), BNP Paribas Financial Markets (0.17%) and China Universal Asset Management Co. Ltd. (0.03%). Insiders that own company stock include Elizabeth A Barrett, Jason Drew Smith, Mark Schoenberg and Molly Henderson. View institutional ownership trends. How do I buy shares of UroGen Pharma? Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:URGN) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe asset beating inflation by 4xColonial MetalsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldElon Musk Secret Crypto Plot ExposedCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsObama’s Forever Term [exposed]Porter & CompanyPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
